Loews Form 4: Harris Receives 2,250 SARs and Sells 2,250 Shares
Rhea-AI Filing Summary
Walter L. Harris, a director of Loews Corporation (L), executed a series of Section 16 transactions under a Rule 10b5-1 trading plan adopted August 7, 2024. On 09/02/2025 he was reported as acquiring 2,250 stock appreciation rights with a $35.52 strike price (received at no cost) that vest/exercise window references 09/30/2015–09/30/2025 and correspond to 2,250 underlying common shares.
On the same date the Form 4 shows additional non-derivative transactions: a disposition of 829 common shares at $96.53 and a sale of 1,421 common shares at $96.69. Following these reported transactions the filing shows 24,343 shares beneficially owned by the reporting person.
Positive
- Transactions executed under a Rule 10b5-1 plan, which provides an affirmative defense and indicates pre-planned trading
- Disclosure filed promptly (Form 4 signed 09/03/2025 by power of attorney), showing compliance with Section 16 timing
Negative
- None.
Insights
TL;DR: Insider executed a pre-planned trading sequence: received SARs and sold shares under a 10b5-1 plan, modest net reduction in beneficial ownership.
The transactions were executed pursuant to an established Rule 10b5-1 plan, which provides an affirmative defense to insider trading claims when properly adopted. The reporting shows receipt of 2,250 stock appreciation rights (no cost grant) and contemporaneous cash dispositions totaling 2,250 shares (829 + 1,421), resulting in reported beneficial ownership of 24,343 shares after the trades. From an earnings-impact perspective these are routine, non-operational insider liquidity events and do not reflect new company performance information.
TL;DR: Governance controls appear followed: trades executed under a dated 10b5-1 plan and Form 4 was filed promptly by power of attorney.
The filing discloses the 10b5-1 plan adoption date (August 7, 2024) and a Form 4 signed via power of attorney on 09/03/2025, indicating compliance with disclosure timing. The mix of a no-cost SAR grant and share sales is consistent with standard director compensation and liquidity management. No departures, related-party transactions, or other governance red flags are disclosed in this Form 4.